BMO Capital on Pfizer (PFE): 'SigVie Trial Misses on OS With Signs of Benefit for Future Trials'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $34.00 price target on Pfizer (NYSE: PFE).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
